Literature DB >> 17911260

Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.

Daniel X Johansson1, Cécile Voisset, Alexander W Tarr, Mie Aung, Jonathan K Ball, Jean Dubuisson, Mats A A Persson.   

Abstract

One way to dissect the antibody response to an invading microorganism is to clone the antibody repertoire from immune donors and subsequently characterize the specific antibodies. Recently, methodological advances have allowed investigations of neutralizing antibodies against hepatitis C virus (HCV) in vitro. We have investigated three human mAbs, previously isolated from an individual infected with HCV of genotype 2b, that are known to cross-react in a binding assay to the envelope E2 protein of genotypes 1a and 1b. We now report that two of them have a neutralizing activity with a breadth not previously observed. Indeed, mAbs 1:7 and A8 recognized E2 from all of the six major genotypes, and they neutralized retroviral pseudoparticles [HCV pseudoparticles (HCVpp)] carrying genetically equally diverse HCV envelope glycoproteins. Importantly, these antibodies were also able to neutralize the cell culture infectious HCV clone JFH-1 in vitro, with IC(50) values of 60 ng/ml and 560 ng/ml, respectively. The conformational epitopes of these two broadly reactive antibodies were overlapping yet distinct and involved amino acid residues in the 523-535 region of E2, known to be important for the E2-CD81 interaction. The third antibody clone, representing a dominant population in the initial screen for these antibodies, was less broadly reactive and was unable to neutralize the genotype 2a infectious clone JFH-1. Our results confirm at the clonal level that broadly neutralizing human anti-HCV antibodies can be elicited and that the region amino acids 523-535 of the HCV envelope glycoprotein E2 carries neutralizing epitopes conserved across all genotypes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911260      PMCID: PMC2042196          DOI: 10.1073/pnas.0705522104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

Review 2.  Prospects for a vaccine against the hepatitis C virus.

Authors:  Michael Houghton; Sergio Abrignani
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

3.  Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation.

Authors:  C Féray; M Gigou; D Samuel; B Ducot; P Maisonneuve; M Reynès; A Bismuth; H Bismuth
Journal:  Ann Intern Med       Date:  1998-05-15       Impact factor: 25.391

4.  Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.

Authors:  Dimitri Lavillette; Alexander W Tarr; Cécile Voisset; Peggy Donot; Birke Bartosch; Christine Bain; Arvind H Patel; Jean Dubuisson; Jonathan K Ball; François-Loïc Cosset
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

5.  Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.

Authors:  M Flint; C Maidens; L D Loomis-Price; C Shotton; J Dubuisson; P Monk; A Higginbottom; S Levy; J A McKeating
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Efficient expression of recombinant human monoclonal antibodies in Drosophila S2 cells.

Authors:  Daniel X Johansson; Katarina Drakenberg; Kathrin H Hopmann; Alexej Schmidt; Fayezeh Yari; Jorma Hinkula; Mats A A Persson
Journal:  J Immunol Methods       Date:  2006-09-25       Impact factor: 2.303

7.  Human antibodies from phage libraries: neutralizing activity against human immunodeficiency virus type 1 equally improved after expression as Fab and IgG in mammalian cells.

Authors:  A Samuelsson; F Yari; J Hinkula; O Ersoy; E Norrby; M A Persson
Journal:  Eur J Immunol       Date:  1996-12       Impact factor: 5.532

8.  Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.

Authors:  Arvind H Patel; Jonny Wood; Francois Penin; Jean Dubuisson; J A McKeating
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

9.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.

Authors:  Mayla Hsu; Jie Zhang; Mike Flint; Carine Logvinoff; Cecilia Cheng-Mayer; Charles M Rice; Jane A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-21       Impact factor: 11.205

10.  Characterization of functional hepatitis C virus envelope glycoproteins.

Authors:  Anne Op De Beeck; Cécile Voisset; Birke Bartosch; Yann Ciczora; Laurence Cocquerel; Zhenyong Keck; Steven Foung; François-Loïc Cosset; Jean Dubuisson
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

View more
  86 in total

1.  Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.

Authors:  Yong Wang; Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Fraser Conrad; Jianlong Lou; Michael Eckart; James D Marks; Steven K H Foung
Journal:  J Biol Chem       Date:  2011-10-14       Impact factor: 5.157

Review 2.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

3.  Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Authors:  Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Yong Wang; Patrick Lau; Thomas Krey; Felix A Rey; Steven K H Foung
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

Review 4.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

5.  Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate.

Authors:  Daire O'Shea; John Law; Adrian Egli; Donna Douglas; Gary Lund; Sarah Forester; Joshua Lambert; Mansun Law; Dennis R Burton; D L J Tyrrell; Michael Houghton; Atul Humar; Norman Kneteman
Journal:  Liver Transpl       Date:  2016-01-29       Impact factor: 5.799

6.  Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.

Authors:  Nicasio Mancini; Roberta A Diotti; Mario Perotti; Giuseppe Sautto; Nicola Clementi; Giovanni Nitti; Arvind H Patel; Jonathan K Ball; Massimo Clementi; Roberto Burioni
Journal:  PLoS One       Date:  2009-12-11       Impact factor: 3.240

7.  A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope.

Authors:  Zhen-Yong Keck; Oakley Olson; Meital Gal-Tanamy; Jinming Xia; Arvind H Patel; Marlène Dreux; Francois-Loïc Cosset; Stanley M Lemon; Steven K H Foung
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

8.  In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.

Authors:  Meital Gal-Tanamy; Zhen-Yong Keck; MinKyung Yi; Jane A McKeating; Arvind H Patel; Steven K H Foung; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-03       Impact factor: 11.205

9.  Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.

Authors:  Partha K Chandra; Sidhartha Hazari; Bret Poat; Feyza Gunduz; Ramesh Prabhu; Gerald Liu; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Virol J       Date:  2010-06-07       Impact factor: 4.099

10.  Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.

Authors:  Ania M Owsianka; Alexander W Tarr; Zhen-Yong Keck; Ta-Kai Li; Jeroen Witteveldt; Richard Adair; Steven K H Foung; Jonathan K Ball; Arvind H Patel
Journal:  J Gen Virol       Date:  2008-03       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.